This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
13 Oct 2014

Merck Millipore to Introduce New Processing Technologies at BPI Conference

Merck Millipore, the life science division of Merck, will be showcasing its new biopharmaceutical processing solutions at the BioProcess International Conference & Exhibition 20–23 October in Boston. These products add to Merck Millipore's complete range of upstream and downstream products, helping to improve manufacturing productivity and accelerate time-to-market.


The new technologies on display at the BioProcess International Conference & Exhibition will include

PureFlex Plus Single-Use Process Container Film
Merck Millipore is introducing PureFlex Plus film, a robust, durable film used in the construction of Mobius single-use process containers for biopharmaceutical manufacturing. The film's rugged outer layer offers strong resistance to leak formation, making it ideal for the demanding applications often encountered in large volume operations.

The PureFlex Plus film can be used throughout the entire manufacturing process. It builds upon Merck Millipore's established PureFlex film technology by adding a new, more robust linear low density polyethlene (LLDPE) outer layer to reduce susceptibility to leaks through abrasion, puncture, stretching and tearing.
 

Cellvento CHO Cell Culture Media
Merck Millipore is expanding its Cellvento CHO cell culture media portfolio of chemically defined, non-animal origin media formulations for batch and fed-batch mode operations. Three new products are launching to specifically address DHFR negative cell lines: Cellvento CHO-110 medium, Cellvento CHO-210 medium and Cellvento Feed-210 media.

Cellvento CHO-110 medium is recommended for batch application and seed train expansion as its rich formulation supports high cell growth. Cellvento CHO-210 medium and its companion feeds are effective at achieving high-density cell growth and competitive productivity with DHFR negative CHO suspension cell types and expression systems, especially recombinant CHO DG44 cell lines.



NovaSeptum Single-Use Holders
NovaSeptum single-use holders are a new component of Merck Millipore's NovaSeptum fully disposable sampling systems, which help prevent contamination when sampling fluids from aseptic and sterile processes. The new single-use holders are compatible with NovaSeptum containers, helping reduce validation requirements, and can be filled with any type of container using a 2-mm trigger.

Ready-to-use, flexible and fully validated, the single-use holders are ideal for manufacturers dealing with recombinant proteins, vaccines and mAbs who need to autoclave before starting their processes.



Chromabolt Chromatography Resins
Merck Millipore is announcing the availability of three new chromatography resins for its Chromabolt prepacked columns. These pre-validated chromatography columns can come packed with either strong cation exchangers, weak cation exchangers or strong anion exchangers, freeing up end users' time and resources by eliminating manual column packing and cleaning.

Chromabolt columns are available in three sizes — 10 cm, 20 cm and 32 cm inner diameter (i.d.) — and are designed for pilot and early clinical manufacturing. The three new resins are Fractogel EMD SE Hicap, Fractogel EMD COO(M), and Eshmuno Q.


Merck Millipore will also be presenting at the BioProcess International Conference & Exhibition:

Integrated Single-Use Purification Technologies Enabling Continuous MAb Processing
Presented by Michael W. Phillips
Director, Technology Development, Merck Millipore
Tuesday, 21 October,12:00 p.m.

The Development of a More Physically Robust Single-Use Fluid Management Film for Demanding Bioprocess Applications
Presented by Michael Felo, Group Product Manager, Single Use, Merck Millipore
Wednesday, 22 October, 1:15 p.m.–1:35 p.m.
BioProcess International Theater

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.